Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

This article was originally published here

In addition, following positive Phase 1/2 study results, a Phase 3 study evaluating rilzabrutinib for ITP has been initiated. Rilzabrutinib received orphan drug designation from the FDA for

The post Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply